Literature DB >> 17368861

Why invest in a national public health program for stroke? An example using Australian data to estimate the potential benefits and cost implications.

Dominique A Cadilhac1, Robert C Carter, Amanda G Thrift, Helen M Dewey.   

Abstract

OBJECTIVES: Stroke is the world's second leading cause of death in people aged over 60 years. Approximately 50,000 strokes occur annually in Australia with numbers predicted to increase by about one third over 10-years. Our objectives were to assess the economic implications of a public health program for stroke by: (1) predicting what potential health-gains and cost-offsets could be achieved; and (2) determining the net level of annual investment that would offer value-for-money.
METHODS: Lifetime costs and outcomes were calculated for additional cases that would benefit if 'current practice' was feasibly improved, estimated for one indicative year using: (i) local epidemiological data, coverage rates and costs; and (ii) pooled effect sizes from systematic reviews.
INTERVENTIONS: blood pressure lowering; warfarin for atrial fibrillation; increased access to stroke units; intravenous thrombolysis and aspirin for ischemic events; and carotid endarterectomy. Value-for-money threshold: AUD$30,000/DALY recovered.
RESULTS: Improved, prevention and management could prevent about 27,000 (38%) strokes in 2015. In present terms (2004), about 85,000 DALYs and AUD$1.06 billion in lifetime cost-offsets could be recovered. The net level of annual warranted investment was AUD$3.63 billion.
CONCLUSIONS: Primary prevention, in particular blood pressure lowering, was most effective. A public health program for stroke is warranted.

Entities:  

Mesh:

Year:  2007        PMID: 17368861     DOI: 10.1016/j.healthpol.2007.02.001

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  6 in total

Review 1.  Disability and disability-adjusted life years: not the same.

Authors:  Scott D Grosse; Donald J Lollar; Vincent A Campbell; Mary Chamie
Journal:  Public Health Rep       Date:  2009 Mar-Apr       Impact factor: 2.792

2.  ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.

Authors:  Michelle J Porritt; Michelle Chen; Sarah S J Rewell; Rachael G Dean; Louise M Burrell; David W Howells
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-21       Impact factor: 6.200

Review 3.  Outcome measurement in economic evaluations of public health interventions: a role for the capability approach?

Authors:  Paula K Lorgelly; Kenny D Lawson; Elisabeth A L Fenwick; Andrew H Briggs
Journal:  Int J Environ Res Public Health       Date:  2010-05-06       Impact factor: 3.390

4.  5-year survival and rehospitalization due to stroke recurrence among patients with hemorrhagic or ischemic strokes in Singapore.

Authors:  Yan Sun; Sze Haur Lee; Bee Hoon Heng; Vivien S Chin
Journal:  BMC Neurol       Date:  2013-10-03       Impact factor: 2.474

5.  Economic Evaluation of a Pre-Hospital Protocol for Patients with Suspected Acute Stroke.

Authors:  Suman Lahiry; Christopher Levi; Joosup Kim; Dominique A Cadilhac; Andrew Searles
Journal:  Front Public Health       Date:  2018-03-05

6.  Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness Analysis of eHealth Tools to Support All Stages of Screening.

Authors:  Jessica Orchard; Jialin Li; Ben Freedman; Ruth Webster; Glenn Salkeld; Charlotte Hespe; Robyn Gallagher; Anushka Patel; Bishoy Kamel; Lis Neubeck; Nicole Lowres
Journal:  J Am Heart Assoc       Date:  2020-08-31       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.